Compare NYAX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NYAX | MLYS |
|---|---|---|
| Founded | 2005 | 2019 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.2B |
| IPO Year | 2022 | 2023 |
| Metric | NYAX | MLYS |
|---|---|---|
| Price | $65.71 | $24.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 7 |
| Target Price | ★ $49.50 | $48.67 |
| AVG Volume (30 Days) | 28.6K | ★ 1.8M |
| Earning Date | 05-12-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 37.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $30.66 | N/A |
| Revenue Next Year | $21.70 | N/A |
| P/E Ratio | $89.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $39.17 | $12.59 |
| 52 Week High | $76.86 | $47.65 |
| Indicator | NYAX | MLYS |
|---|---|---|
| Relative Strength Index (RSI) | 41.09 | 38.88 |
| Support Level | $63.03 | $22.42 |
| Resistance Level | $75.85 | $31.29 |
| Average True Range (ATR) | 1.69 | 1.66 |
| MACD | -1.02 | -0.69 |
| Stochastic Oscillator | 2.82 | 20.53 |
Nayax Ltd is an end-to-end retail technology platform for unattended commerce. It unifies payments, operations management, and customer engagement tools into a powerful, adaptable platform for modern commerce. It provides solutions that empower businesses to enhance customer experience, accept cashless payments, and manage their operations with a robust Internet of Things (IoT) software platform, helping achieve long-term growth. The company addresses a broad range of retail verticals, including all types of vending machines, coffee machines, unattended checkout counters, self-service kiosks, ticketing machines, car wash stations, gaming machines, amusement rides, laundromats, EV charging stations, and many more.
Mineralys Therapeutics Inc is a biopharmaceutical company focused on developing medicines to target diseases driven by dysregulated aldosterone. The Company's product candidate, lorundrostat, is a proprietary, orally administered, aldosterone synthase inhibitor that the Company is developing for the treatment of cardiorenal conditions affected by dysregulated aldosterone, including hypertension and related comorbidities, such as chronic kidney disease and obstructive sleep apnea. Its product candidate, lorundrostat, is a proprietary, orally administered, selective ASI that is designed to reduce aldosterone levels by inhibiting CYP11B2, the enzyme responsible for producing the hormone.